AI summary · may contain errors
Postsurgical ctDNA-defined MRD positivity after upfront resection of colorectal liver metastases is linked to worse DFS (HR 4.14) and OS (HR 9.13).
- 1 cited this week
- Open access
Moving in Cancer Cell and JAMA Oncology.
Rebuilt
AI summary · may contain errors
Postsurgical ctDNA-defined MRD positivity after upfront resection of colorectal liver metastases is linked to worse DFS (HR 4.14) and OS (HR 9.13).
AI summary · may contain errors
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
Newest first · last 60 days
AI summary · may contain errors
Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in resectable non-metastatic colorectal cancer, achieving 41% (95% CI, 21%-64%) in pMMR and 100% (95% CI, 40%-100%) in dMMR.
AI summary · may contain errors
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
AI summary · may contain errors
Molidustat, a PHD2 inhibitor, induces cell death in human APC-mutant colorectal cancer cells via off-target inhibition of GSTP1, linked to a GSTP1–PHD2 synthetic lethal interaction.
AI summary · may contain errors
Redirecting intestinal cholesterol metabolism via gut microbiota generates 4-cholesten-3-one (4-C-3), which suppresses colorectal cancer growth and enables regression in preclinical models.
AI summary · may contain errors
Dynamic ctDNA methylation–guided surveillance in nonmetastatic colorectal cancer after curative resection increases curative-intent metastasis-directed therapy rates (48.1% vs 23.6%).
AI summary · may contain errors
In RAS/BRAF wild-type, left-sided metastatic colorectal cancer, m-FOLFOXIRI plus cetuximab improved median progression-free survival to 14.8 vs 11.9 months versus bevacizumab.
AI summary · may contain errors
Multiomic profiling of microsatellite-stable (MSS) colorectal cancer across ~2,000 tumors identifies targetable vulnerabilities, including MEK-combination sensitivities in RAS-mutant MSS CRC models.
AI summary · may contain errors
Multi-omics profiling of microsatellite-stable colorectal cancer, integrated with patient-derived models, identifies focal adhesion kinase and phosphoinositide-dependent kinase 1 as promising therapeutic targets.
AI summary · may contain errors
Label-free bottom-up proteomics of 122 colorectal tumor and matched normal samples from 61 patients shows MSS CRC proteomes are significantly distinct from three MSI-high Lynch-related subtypes.
AI summary · may contain errors
Image-based consensus molecular subtyping (imCMS) of stage II/III colorectal cancer in the SCOT trial is strongly prognostic independent of clinicopathologic factors, dMMR, and CD8 IE -FoxP3 IS.
AI summary · may contain errors
Cell-of-origin position along the vertical axis of the intestinal crypt is linked to distinct oncogenic escape mechanisms, shaping morphologically discrete precursor lesions and later colorectal cancer heterogeneity.
AI summary · may contain errors
PROTAC-mediated degradation of tankyrase (TNKS) overcomes AXIN puncta–driven resistance that limits catalytic TNKS inhibitors, enabling deeper WNT/β-catenin suppression in colorectal cancer cells with dysfunctional APC mutations.
AI summary · may contain errors
β-catenin, encoded by CTNNB1, is part of a major WNT oncogenic axis present in approximately 10% of human cancers, making it a prime precision oncology target.
AI summary · may contain errors
ADORA1-FASN–palmitic acid metabolic reprogramming is linked to therapy-induced senescence and oxaliplatin resistance in colorectal cancer, with ADORA1 induced by oxaliplatin and enriched in chemoresistant patients.
AI summary · may contain errors
Tinengotinib showed clinical benefit in 27.0% of evaluable patients with advanced solid tumors, with antitumor activity strongest at 10 mg and 12 mg once daily.
AI summary · may contain errors
A 37-gene ColoTubIn signature predicts paclitaxel sensitivity in patient-derived colon cancer models, with low scores linked to increased drug responsiveness.
AI summary · may contain errors
Botensilimab plus balstilimab produced an objective response rate of 21% in 123 patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, with 36-month OS of 33%.
AI summary · may contain errors
Ulixertinib showed no objective responses (ORR 0%) in 34 pancancer patients with BRAF fusions or non-V600E/non-V600K BRAF mutations.
AI summary · may contain errors
EMB-01 given weekly at 1,600 mg showed a confirmed objective response rate of 12.5% in 48 heavily pretreated metastatic colorectal cancer patients.
AI summary · may contain errors
Transarterial radioembolization monotherapy is the only hepatocellular carcinoma (HCC) macrovascular invasion option with consistently low heterogeneity, yielding pooled 1-year overall survival of 34% (95% CI 20%–48%).
Journals this month
Topics moving, week to 17 Nov 2026
By field